Our lead product for severe pneumonia, plasma gelsolin, has application for COVID19.

Share on facebook
Share on twitter
Share on linkedin

March, 2019: BioAegis Therapeutics Awarded European Patent Protection for the Uses of Plasma Gelsolin to Treat Infections

MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) March 13, 2019 BioAegis Therapeutics Inc., a privately held biotechnology company commercializing plasma gelsolin (pGSN), an endogenous human protein that harnesses the innate immune system to modulate the inflammatory response as well as boost the capacity of immune cells to fight infection announced today that the European Patent Office has issued a patent for the Use of Plasma Gelsolin to Treat Infections.  This grant adds to BioAegis’ infection portfolio already covered by patents in the US, China and other territories.

Read the full press release here: European Infection Patent